{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:15:46Z","timestamp":1787030146163,"version":"build-2736575974"},"reference-count":28,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Sciences"],"abstract":"<jats:p>Immune-mediated non-neoplastic bone marrow disorders (NNBMD), including precursor-targeted immune-mediated anemia (PIMA) and myelodysplastic syndrome (MDS), can cause non-regenerative anemia in dogs and often fail to respond to immunosuppressive treatment. Human intravenous immunoglobulin (hIVIG) has been proposed as an immunomodulatory therapy for refractory hematologic disease in humans, but evidence in veterinary patients remains limited. This case report describes the adjunctive use of hIVIG and the associated clinical responses observed in two dogs with refractory NNBMD. A 10-year-old (3.2 kg) spayed female Maltese (case 1) showed persistent non-regenerative anemia, with hematocrit (HCT) 15.6\u201320.2% and reticulocyte production index (RPI) 0.12\u20130.69, requiring four transfusions over 10 months, and was diagnosed with PIMA based on bone marrow cytology demonstrating destruction of erythroid precursors. A 7-year-old (9.3 kg) intact female Dachshund (case 2) had sustained non-regenerative anemia (HCT 10.8\u201320.9%, RPI 0.12\u20130.40) necessitating eight transfusions over 20 months and was diagnosed with MDS characterized by dyserythropoiesis. Human intravenous immunoglobulin (0.5 g\/kg over 6 h) was administered six times in case 1 and seven times in case 2 over a four-month period. After initiating hIVIG therapy, RPI increased (0\u21921.80 and 0.25\u21922.10 in cases 1 and 2), and HCT remained above 20% without further transfusions. To our knowledge, this is the first clinical report demonstrating the adjunctive use of hIVIG and associated hematologic improvement in canine NNBMD.<\/jats:p>","DOI":"10.3390\/vetsci13020145","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:00:58Z","timestamp":1770109258000},"page":"145","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of Human Intravenous Immunoglobulin Therapy in Two Dogs with Non-Neoplastic Bone Marrow Disorders Refractory to Immunosuppressive Therapy"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8084-950X","authenticated-orcid":false,"given":"Eun-Ji","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Veterinary Emergency and Critical Care, College of Veterinary Medicine, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Jung","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Veterinary Emergency and Critical Care, College of Veterinary Medicine, Konkuk University, Seoul 05029, Republic of Korea"},{"name":"KU Center for Animal Blood Medical Science, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1939-1676.2000.tb02264.x","article-title":"Primary myelodysplastic syndromes of dogs: A report of 12 cases","volume":"14","author":"Weiss","year":"2000","journal-title":"J. Vet. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2460\/javma.2000.216.1429","article-title":"Idiopathic pure red cell aplasia and nonregenerative immune-mediated anemia in dogs: 43 cases (1988\u20131999)","volume":"216","author":"Stokol","year":"2000","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1292\/jvms.19-0439","article-title":"Clinical and clinicopathological features and outcomes of Miniature Dachshunds with bone marrow disorders","volume":"82","author":"Tani","year":"2020","journal-title":"J. Vet. Med. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2460\/javma.1998.213.07.999","article-title":"Use of human recombinant erythropoietin and prednisone for treatment of myelodysplastic syndrome with erythroid predominance in a dog","volume":"213","author":"Boone","year":"1998","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1292\/jvms.23-0010","article-title":"Investigation of the therapeutic effects, predictors, and complications of long-term immunosuppressive therapy in dogs with precursor-targeted immune-mediated anemia","volume":"85","author":"Morishita","year":"2023","journal-title":"J. Vet. Med. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2460\/javma.255.3.366","article-title":"Clinical features of precursor-targeted immune-mediated anemia in dogs: 66 cases (2004\u20132013)","volume":"255","author":"Assenmacher","year":"2019","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.cvsm.2020.07.015","article-title":"Use of human intravenous immunoglobulin in veterinary clinical practice","volume":"50","author":"Spurlock","year":"2020","journal-title":"Vet. Clin. N. Am. Small Anim. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1476-4431.2011.00676.x","article-title":"A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin","volume":"21","author":"Spurlock","year":"2011","journal-title":"J. Vet. Emerg. Crit. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/vcp.12502","article-title":"Histologic and cytologic bone marrow findings in dogs with suspected precursor-targeted immune-mediated anemia and associated phagocytosis of erythroid precursors","volume":"46","author":"Lucidi","year":"2017","journal-title":"Vet. Clin. Pathol."},{"key":"ref_10","unstructured":"Roback, J.D., Grossman, B.J., Harris, T., and Hillyer, C.D. (2011). Technical Manual, AABB. [17th ed.]."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1939-165X.2001.tb00261.x","article-title":"Cytologic evaluation of primary and secondary myelodysplastic syndromes in the dog","volume":"30","author":"Weiss","year":"2001","journal-title":"Vet. Clin. Pathol."},{"key":"ref_12","first-page":"44","article-title":"Myelodysplasia: Differentiating neoplastic from nonneoplastic syndromes of ineffective hematopoiesis in dogs","volume":"31","author":"Blue","year":"2003","journal-title":"Toxicol. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1939-165X.1991.tb00571.x","article-title":"Proposed criteria for classification of acute myeloid leukemia in dogs and cats","volume":"20","author":"Jain","year":"1991","journal-title":"Vet. Clin. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.5455\/OVJ.2023.v13.i9.16","article-title":"Complete remission of two canine cases with precursor-targeted immune-mediated anemia after combination therapy with prednisolone, cyclosporine, and oclacitinib","volume":"13","author":"Yuki","year":"2023","journal-title":"Open Vet. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5326\/15473317-35-6-475","article-title":"Long-term case study of myelodysplastic syndrome in a dog","volume":"35","author":"Miyamoto","year":"1999","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.V126.23.1704.1704","article-title":"Intravenous immunoglobulin is an effective treatment for LGL-mediated immune cytopenias in myelodysplastic syndromes","volume":"126","author":"Schieppati","year":"2015","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1073\/pnas.89.8.3325","article-title":"Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain","volume":"89","author":"Marchalonis","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2005.02834.x","article-title":"Clinical uses of intravenous immunoglobulin","volume":"142","author":"Jolles","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1476-4431.2009.00433.x","article-title":"Use of mycophenolate mofetil as a rescue agent in severe generalized myasthenia gravis in three dogs","volume":"19","author":"Abelson","year":"2009","journal-title":"J. Vet. Emerg. Crit. Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1939-1676.2006.tb00770.x","article-title":"The use of intravenous human immunoglobulin in treatment of severe pemphigus foliaceus in a dog","volume":"20","author":"Rahilly","year":"2006","journal-title":"J. Vet. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.2460\/ajvr.1998.59.12.1568","article-title":"Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes","volume":"59","author":"Reagan","year":"1998","journal-title":"Am. J. Vet. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"ref_23","first-page":"100","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy and other immune neuropathies: A systematic review","volume":"80","author":"Eftimov","year":"2013","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM198608073150601","article-title":"The treatment of Kawasaki syndrome with intravenous gamma globulin","volume":"315","author":"Newburger","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1939-1676.1997.tb00475.x","article-title":"Intravenous human immunoglobulin for the treatment of immune-mediated hemolytic anemia in 13 dogs","volume":"11","author":"Kellerman","year":"1997","journal-title":"J. Vet. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jsap.13700","article-title":"Use of human intravenous immunoglobulin for the treatment of 12 dogs with newly diagnosed malignant disease and presumed secondary immune-mediated thrombocytopenia","volume":"65","author":"Stikeman","year":"2024","journal-title":"J. Small Anim. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2165\/00002018-199309040-00003","article-title":"Adverse effects of intravenous immunoglobulin","volume":"9","author":"Misbah","year":"1993","journal-title":"Drug Saf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/nu2030299","article-title":"Vitamin B12 in health and disease","volume":"2","author":"Samman","year":"2010","journal-title":"Nutrients"}],"container-title":["Veterinary Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-7381\/13\/2\/145\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:38:47Z","timestamp":1770111527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-7381\/13\/2\/145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["vetsci13020145"],"URL":"https:\/\/doi.org\/10.3390\/vetsci13020145","relation":{},"ISSN":["2306-7381"],"issn-type":[{"value":"2306-7381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}